Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15027057,potency ratio,"Using quantitative analysis of regional paralysis produced by local injections into the gastrocnemius muscles of mice, prior studies estimated the potency ratio between Dysport and BOTOX to be 4.2 to 1.",Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15027057/),,4.2 to 1,30609,DB00083,Botulinum Toxin Type A
,20405003,half-life,One such molecule has an in vivo half-life of 6.5 hours and is devoid of obvious sign of toxicity.,Small molecules showing significant protection of mice against botulinum neurotoxin serotype A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20405003/),h,6.5,34571,DB00083,Botulinum Toxin Type A
,30959899,LD50,"Botulinum neurotoxins (BoNT) are some of the most toxic proteins known, with a human LD50 of ~1 ng/kg.",Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30959899/),[ng] / [kg],1,159659,DB00083,Botulinum Toxin Type A
less,30959899,half-life in circulation,Equine antitoxin has a half-life in circulation of less than 1 day and is limited to a treatment rather than a prevention indication.,Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30959899/),d,1,159660,DB00083,Botulinum Toxin Type A
>,30959899,half-lives,The development of monoclonal antibodies (mAbs) may represent an alternative therapeutic option that can be produced at high quantities and of high quality and with half-lives of >10 days.,Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30959899/),d,10,159661,DB00083,Botulinum Toxin Type A
